Corporate Overview

Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specializes in the discovery and development of innovative therapies for the treatment of immune-mediated disorders. The company’s therapeutic approaches are aimed at restoring balance to the immune system in conditions associated with aberrant and harmful immune responses, such as autoimmune and inflammatory disorders, graft rejection, cancer and chronic viral diseases. TTI is primarily involved in the development of protein therapeutics, such as monoclonal antibodies, secreted proteins and peptides.

The company’s business model is to identify therapeutic candidates that have shown promise in animal models and to rapidly advance these into clinical testing. TTI is concentrating its efforts on preclinical and early clinical drug development, with the primary objective of demonstrating safety and efficacy in man. TTI has chosen to establish development partnerships for some of its projects at a preclinical stage, and anticipates advancing several others into clinical development on its own.

TTI has three scientific programs containing six product opportunities at various stages of preclinical testing. One program focuses on the immunoregulatory protein CD200 and its receptor, a second is based upon the activating Fc receptor FcgRIIa (CD32a) and the third involves the use of a growth factor in the treatment of gastrointestinal inflammation and damage. The company has numerous research collaborations that provide access to world-class laboratories and a series of discovery projects.